In this issue:
MM response impact on bone-directed therapy
Pomalidomide, cyclophosphamide and prednisone for relapsed/ refractory MM
Panobinostat+bortezomib and dexamethasone in relapsed and bortezomib-refractory MM
Bortezomib induction, reducedintensity SCT and lenalidomide consolidation/maintenance
CKD-EPI-CysC predicts OS in new MM
MGUS: a new workup proposal
VTE risk in lenalidomidetreated MM
Second-line bortezomib+dexamethasone ±cyclophosphamide or lenalidomide for MM
Bortezomib vs. nonbortezomib induction pre-SCT in untreated MM
Please login below to download this issue (PDF)